Share Tips 2024: Finance Monthly's Leading Selections for This Week

As we navigate through 2024, investors keen on maximizing their portfolios are always in search of the latest stock recommendations. This week, Finance Monthly highlights a selection of promising stocks to consider for your investment strategy. By consolidating insights from top analysts in the UK and international markets, we provide you with a valuable resource to identify key opportunities.

1. Tesco (LON: TSCO) - Source: The Telegraph

Tesco is positioned “exceptionally well” to capitalize on the growing purchasing power of consumers as inflation and interest rates begin to stabilize. The company recently reported a 4% increase in half-year sales and an impressive 24% rise in earnings per share, leading to an upgrade in its full-year guidance. Proceeds from the divestiture of its banking division are expected to bolster share buybacks. With a strong market presence and a loyal customer base, Tesco is poised for enhanced profit margins through potential price increases. Despite a significant debt level, the outlook remains positive.
Recommendation: Continue to buy at 351p.

2. ASML (AMS: ASML) - Source: The Times

ASML's stock experienced a 15% drop following warnings of a slower recovery in the semiconductor sector and a lowered sales forecast for 2025. Factors such as the impact of China on the chip market and reduced capital expenditures from major client Intel may pose challenges. However, modest sales growth is expected as chip manufacturing facilities expand and prices increase. With a near-monopoly in a critical segment of the supply chain, ASML's shares are currently priced lower than those of its competitors, making them attractive for long-term investors.
Recommendation: Buy at €662.

3. Futura Medical (LON: FUM) - Source: This is Money

Futura Medical has launched its erectile dysfunction treatment, Eroxon, in over ten countries, including the UK and the US. This product is notable as the first clinically validated topical gel for the treatment of ED, presenting a significant revenue growth opportunity. Research indicates that peak annual sales could reach $350 million by the fifth year, with distribution partners managing promotional costs.
Recommendation: Buy at 33p.

4. Netcall (LON: NET) - Source: Shares

Netcall has successfully transformed into a software enterprise through strategic acquisitions. Its Liberty cloud subscription service platform has shown strong cash flow and consistent sales growth. Gresham House, the largest shareholder, sees potential for revaluation or acquisition by private equity firms. As the company integrates generative AI into its platform, it is a favorable time to invest.
Recommendation: Buy at 88p.

5. Schneider Electric (EPA: SU) - Source: Investors’ Chronicle

Schneider Electric specializes in solutions for electrification across diverse applications. The company expects a 5% sales increase, reaching $41 billion in 2024, driven by the rising demand for electricity in AI data centers. Analysts forecast an average annual earnings growth of approximately 13% over the next two years. With the acquisition of Motivair to enhance its position in the liquid-cooling technology sector, Schneider is well-equipped to support companies in reducing carbon emissions.
Recommendation: Buy at €240; JP Morgan has set a price target of €270.

6. Tesla (NASDAQ: TSLA) - Source: The Times

In the third quarter, Tesla reported a 2% increase in car sales, exceeding $20 billion in revenue, and a 17% rise in profits to $2.2 billion. CEO Elon Musk projects a growth rate of 20%-30% in vehicle sales by 2025 as Tesla aims to lead in artificial intelligence and analytics, beyond automotive manufacturing. The company is also developing an autonomous Robotaxi and plans to invest $10 billion in expanding its data centers. However, Tesla faces competition, and advancements in autonomous vehicle technology may progress slowly.
Recommendation: Hold at $262.

7. Town Centre Securities (LON: TOWN) - Source: The Telegraph

Despite certain risks, including limited liquidity and uncertainties in the commercial real estate market due to hybrid work trends, Town Centre Securities is trading at nearly a 50% discount to its net asset value (NAV). The company has restructured its portfolio, reduced debt levels, and diversified operations. An improving economic landscape, along with new planning consents for residential projects and initiatives in student accommodation, could enhance its performance.
Recommendation: Buy at 136p.

8. Glencore (LON: GLEN) - Source: Investors’ Chronicle

Amid shifting investor sentiment regarding coal, Glencore has decided to maintain its coal mining operations. Recent projections from the International Energy Agency indicate an uptick in coal demand through 2030. While Glencore derives most of its profits from mining, its trading division provides significant leverage during market volatility. Despite rising costs, a robust balance sheet and growing copper demand from the energy transition position Glencore well for future growth.
Recommendation: Buy at 404p.

9. GSK (LON: GSK) - Source: The Times

GSK is showing signs of recovery, particularly in its vaccine division, which is expected to drive significant revenue growth. The company is benefiting from increased demand for its shingles vaccine and continued strong performance from its respiratory portfolio. Analysts anticipate robust earnings growth, positioning GSK as a solid investment opportunity.
Recommendation: Buy at 1650p.

Disclaimer

The information provided in Finance Monthly is for informational purposes only and should not be construed as investment advice. All content, including articles, interviews, and analysis, reflects the opinions of the authors and does not necessarily represent the views of Finance Monthly.

Investing in financial markets involves risks, including the loss of principal. Past performance is not indicative of future results, and there is no guarantee that any investment strategy will be successful. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.

Finance Monthly is not responsible for any losses or damages arising from reliance on the information contained herein. By accessing this publication, you acknowledge and accept these terms.